Abstract. To investigate the possibility that natural medicines affect lipid metabolism by regulating lipoprotein lipase (LPL) expression, a green fluorescent protein (GFP) gene was constructed downstream of the peroxisome proliferator response element (PPRE) and the constructed plasmid was microinjected into Xenopus oocytes to establish a PPRE regulatory reporter system. Using this system, hawthorn flavonoids were quickly selected from a panel of natural medicines and found to up-regulate GFP expression by an effect on PPRE. To confirm the effect of hawthorn flavonoids, we treated mice orally with water (control), hawthorn flavonoids, and pioglitazone and measured the LPL levels in serum, adipose tissue, and muscle by an enzyme-linked immunosorbent assay. The serum LPL levels were no different from the controls after treatment with either hawthorn flavonoids or pioglitazone, but LPL increased significantly in muscular tissues and decreased in adipose tissues. These results demonstrate that hawthorn flavonoids meditate LPL expression in mice with tissue-specific differences. A novel PPRE regulatory report system was established for rapid and effective selection and evaluation of LPL-mediating drugs.
Introduction
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear hormone receptor that forms a heterodimer with the retinoid X receptor and binds to a recognition site, proliferator response element (PPRE), which has been identified in several adipocyte-specific genes [e.g., lipoprotein lipase (LPL), phosphoenol pyruvate carboxykinase, aP2, fatty acid transport protein-1, acyl-CoA synthase] (1 -3). PPARγ has critical roles in glucose and lipid metabolism, macrophage function, and adipogenesis. PPARγ agonists such as prostaglandins, leukotrienes, hydroxy-eicosatetraenoic acids, and polyunsaturated fatty acids regulate the expression of genes downstream of PPRE (4, 5) . Since PPARγ is the key regulator of adipocyte differentiation and energy metabolism, synthetic agonists such as thiazolidinediones (TZDs) can be used to treat Type 2 diabetes by decreasing insulin resistance (2) . Loss-of-function studies have shown that PPARγ is required for adipogenesis in vivo and in vitro (6 -8) , so adipocytes have been used in many experiments to characterize both exogenous and endogenous ligands for this receptor (9, 10) . Pancreatic cancer cells (11) , macrophages (12) , neuronal cells (13) , and other lines have also been used to study the functions of PPARγ ligands. Here we report a novel PPRE regulatory report system established in Xenopus oocytes. This system is suitable for rapid selection or evaluation of drugs that might meditate LPL expression via the PPRE pathway.
Since 1971, when Gurdon and his colleagues demonstrated that the fully-grown Xenopus oocyte could translate injected messenger RNAs (14) , this cell type has proved valuable for studying RNA expression and recombinant DNA plasmids (15, 16) . In contrast to somatic cells cultured in vitro, stage VI oocytes are arrested in prophase of meiosis I. Most proteins expressed in somatic cells are not found in oocytes. The Xenopus oocyte, particularly when fully-grown, has become an attractive model for experiments involving the in vitro synthesis of exogenous proteins. Using this model, we have constructed a human peroxisome proliferator response element regulatory system by coinjecting two genes: a destabilized enhanced green fluorescent protein gene, d2EGFP (destabilized variant of the enhanced green fluorescent protein gene having an in vivo half-life of approximately 2 h), which was constructed downstream of PPRE, and the PPARγ gene, which was subcloned downstream of the Xenopus oocyte transcription factor IIIA (TFIIIA) gene promoter (17) . Using this system, we found that hawthorn flavonoids regulated the expression of LPL in vivo. Hawthorn flavonoids were extracted from the traditional Chinese herb hawthorn leaves, used clinically for treating cardiovascular diseases and regulating body lipids.
Materials and Methods

Reagents
Hawthorn flavonoids (≥93.8% pure total flavonoids extracted from hawthorn leaves) were obtained from Jincheng Zhongjin Medicine Co., Ltd. (Jincheng, China); prostaglandin E 1 (PE1) from Hangzhou Meiya Biotechnology Co., Ltd. (Hangzhou, China); pioglitazone from Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, China); tanshinoneIIA from MDidea Exporting Division (Shenzhen, China); and curcumin from the Delta Information Centre for Natural Organic Compounds (Xuancheng, China). Emodin and ginkgo lactone C were obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijiang, China). LPL was obtained from Toyobo Co., Ltd. (Osaka), and collagenase type II from Sigma (St. Louis, MO, USA). All the restriction endonucleases were obtained from MBI (Hannover, CA, USA), except BlnI (AvrII), which was from Takara (Ohtsu). Mouse monoclonal antibodies, anti-bovine LPL, and IgY (chicken egg yolk immunogloblin G) anti-human LPL were prepared in our own laboratory, Department of Life Science, Zhejiang College of Traditional Chinese Medicine, China. Goat IgG-HRP (horseradish peroxidase labeled IgG) anti-chicken IgG was obtained from the KPL Company (Gaithersburg, MD, USA). All other reagents were purchased without further purification from Shanghai Sangon (Shanghai, China). 
Animals
Plasmids
The sequences PPRE (−169 to −157, 5'-TGCCCTTT CCCCC-3') (18), CT element (−91 to −83, 5'-CCTCCC CCC-3') and NF-y binding site (−70 to −56, 5'-TATAG CCAATAGGTG-3') in the promoter region of the human LPL gene (NCBI, NT_030737, see Fig. 1A ) were synthesized by Shanghai Sangon and transferred into the vector pET17B, designated pET17B-PPRE. A destabilized variant of the enhanced green fluorescent protein (d2EGFP) was removed from the plasmid pCRE-d2EGFP (Cat.# 6034-1; Clontech, Mountain View, CA, USA) by digesting with BglII and XhaI and transferred into the pSP vector, designated pSPd2EGFP. The d2EGFP gene was taken from vector pSPd2EGFP by digestion with NheI and XhoI and constructed downstream of PPRE in the pET17B-PPRE vector to obtain plasmid pET17B-PPRE-d2EGFP. The PPRE-d2EGFP fragment was taken from pET17B-PPRE-d2EGFP by digestion with SalI and XbaI and inserted into the multiple cloning site (SalI/AvrII) of the vector pLXRN (K1063-1, Clontech). The resulting plasmid was designated pLXRN-PPRE-d2EGFP (Figs. 1B and 2). The negative gene control plasmid pLXRNd2EGFP (without PPRE) was constructed by inserting the d2EGFP gene, obtained from the pSP-d2EGFP vector by digesting with BglII and XhoI, directly into the multiple cloning site of plasmid pLXRN (Fig. 1C) .
The TFIIIA gene promoter [5'-GGCTACAGTG-3'] of Xenopus oocytes (XOE) was synthesized by Shanghai Sangon and transferred into the vector pET17B, producing a new oocyte expression vector, pET17B-XOE. The human PPARγ gene, obtained from a vector containing human PPAR cDNA (HIBBB54, ATCC) by digesting with HindIII and NotI, was subcloned into the oocyte expression vector pET17B-XOE downstream of XOE. The resulting plasmid was designated pXOE-PPARγ. To examine XOE function in the oocytes, the d2EGFP gene was taken from vector pSP-d2EGFP by digesting with NheI and XhoI and inserted downstream of XOE of pET17B-XOE vector, producing vector pXOE-d2EGFP.
Oocytes
Full-grown oocytes arrested in prophase stage V -VI were obtained from Xenopus laevis ovaries by treatment with 1 mg ⋅ ml tin, and a white dot is observed on the top of the animal pole. The batch was used for expression experiments only if over 90% of the oocytes entered GVBD in 4 -6 h.
Intranuclear microinjection is a skill acquired through practice. The nucleus is situated near the top of the animal hemisphere. Microinjections were made beside the top at a 60°-80° angle, and no further pressure was applied after the capillary pipette needle had penetrated the cell membrane. Before the formal experiments, 20 nl 0.5% of trypan blue was injected into the nuclei of test oocytes, which were fixed in 5% trichloroacetic acid for 10 min and dissected to check the nuclei for trypan blue. Formal experiments were conducted only when the manipulator had successfully injected more than 95% of the test oocytes.
d2EGFP expression in Xenopus oocytes
The GFP reporter system was used to detect the expression of pLXRN-PPRE-d2EGFP. Oocytes with 10 nl of 0.5 µg ⋅ µl −1 plasmid pLXRN-PPRE-d2EGFP and 0.1 µg ⋅ µl −1 pXOE-PPARγ co-injected into their nuclei were divided into 5 groups (150 cells per group), which were treated, respectively, with 2.5, 5, and 10 µg ⋅ ml −1 hawthorn flavonoids, 20 µmol ⋅ l −1 PE1, and drug-free MBS. The negative control group oocytes were co-injected with plasmid pLXRN-d2EGFP and pXOE-PPARγ.
To establish XOE function, another 150 oocytes were injected intranuclearly with plasmid pXOE-d2EGFP. Expression of d2EGFP was detected after 3 days' incubation at 20°C. Ten good quality oocytes from each group were selected, placed on microscope slides (one cell per slide), crushed by a cover slip, and observed under the fluorescence microscope (Leica DMIL, Welzlar, Germany). To quantify the fluorescence intensities of the expressed d2EGFP, 50 good quality oocytes from each group were divided into 5 sets of 10 and placed in a 0.5 ml Eppendorf tube. MBS (200 µl) was added to each tube, the cells were crushed, and the suspension was homogenized with a pipette. The fluorescence intensities were measured using a GFP analyzer (FA-48GFP; BIOER Technology Co., Ltd., Hangzhou, China). A tube with 10 control oocytes (without microinjection or other treatment) was used to measure the background.
LPL in Xenopus oocytes
To analyze effects on LPL expression, the oocytes were microinjected with 10 nl of 0.1 µg ⋅ µl −1 plasmid pXOE-PPARγ. They were distributed among three 24-well plates and divided into 5 groups (each comprising 6 wells with 50 cells) and treated with 2.5, 5, or 10 µg ⋅ ml −1 hawthorn flavonoids, 20 µmol ⋅ l −1 PE1 or drug-free MBS, respectively. Another set of cells was microinjected with 10 nl of sterile water as a control. After 3 days' incubation, the oocytes were mashed and 1.5 ml PBS was added to each well. The suspensions were centrifuged for 5 min at 12,000 rpm at 4°C. The supernatant was used for quantitative analysis of LPL by sandwich-ELISA (enzyme labeling linked immunosorbent assay). An aliquot (100 µl) of supernatant was taken from each sample and added to a 96-well plate coated with mouse monoclonal antibody anti-bovine LPL (2.0 µg ⋅ ml −1 in phosphate-buffered saline (PBS)). To 6 empty wells, 100 µl of 0, 5, 10, 50, 100, and 150 ng ⋅ ml −1 LPL was added to obtain a standard curve. Chicken IgY anti-human LPL was used as the primary antibody and goat IgG-HRP anti-chicken IgG as the secondary antibody.
The LPL content of every 50 oocytes in each group was calculated by the following equation:
LPL in mouse tissues
Fifty mice were divided into 5 groups, with 5 males and 5 females in each group, as a randomized controlled trial (RCT). The negative control group was treated with distilled water; the positive control group with 10 mg ⋅ kg Each mouse received the treatment (1 ml / day) by oral administration for 8 days. Serum was obtained from each mouse 6 h after the final treatment and stored at −20°C for LPL measurement. Hind limb muscles and celiac adipose tissues were prepared by homogenization in PBS (1:1, W / V, pH 7.4) in an ice bath for 15 min. The homogenate was centrifuged for 15 min at 8000 rpm, 4°C; and the supernatant was stored at −20°C for measurement of LPL concentration. The amounts of LPL in the serum, adipose tissue, and muscle samples from each mouse were determined by sandwich-ELISA.
Statistical analysis
The data were compared by a two-tailed Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
d2EGFP expression in Xenopus oocytes
The regulation of LPL expression by the PRRE regulatory d2EGFP report system in the Xenopus oocytes was investigated. In oocytes co-injected with
Content of LPL =
Content of LPL (ng / ml)*1.5 ml *50 (ng/ 50 oocytes) 50 ooctyes plasmids pLXRN-PPRE-d2EGFP and pXOE-PPARγ, the d2EGFP expressed in the PE1, pioglitazone, and hawthorn flavonoid groups was observed under the fluorescence microscope and measured by the GFP analyzer. Their d2EGFP signal intensities were 85.8, 64.9, and 90.3, respectively. No d2EGFP signal was detected in oocyte groups treated with the natural medicines tanshinone, curcumin, emodin, and ginkgo lactone C. In the negative control groups, none of the drugs induced d2EGFP expression. The hawthorn flavonoid was therefore selected for investigating the expression of genes downstream of PPRE via the PPRE regulatory system.
Oocytes co-injected with plasmids pLXRN-PPREd2EGFP and pXOE-PPARγ were treated with different concentrations of hawthorn flavonoids. The amount of d2EGFP expressed increased in a dose-dependent manner ( Fig. 3: A -C). Oocytes injected with plasmid pXOE-d2EGFP and treated with normal MBS also expressed d2EGFP (Fig. 3E ). This demonstrates that the TFIIIA promoter (XOE) can promote downstream PPARγ expression.
LPL in Xenopus oocytes
The amount of endogenous LPL expressed in each oocyte group was detected by sandwich-ELISA. A standard curve was obtained using 100 µl of pure LPL (ng ⋅ ml In the groups injected with plasmid pXOE-PPARγ or with water, hawthorn flavonoids and PE1 increased the expression of LPL significantly compared to MBStreated oocytes. The stimulation of expression was greater in the plasmid-injected cells (Table 1) .
LPL in mouse tissues
The in vivo mouse experiments also demonstrated that hawthorn flavonoids mediate LPL expression of LPL. The serum LPL levels in both the hawthorn flavonoid and pioglitazone groups were no different from the controls. However, the LPL mass increased significantly in muscular tissues and decreased in adipose tissues in response to these treatments ( Table 2) .
Discussion
By co-injecting plasmids pLXRN-PPRE-d2EGFP and pXOE-PPARγ, we established a PPRE regulatory d2EGFP reporter system in Xenopus oocytes (Fig. 4) . Using this system, the human PPARγ gene was constructed downstream of the Xenpous TFIIIA gene promoter (XOE). Xenpous TFIIIA is the first factor to bind to the oocyte-specific 5S RNA gene during assembly of the preinitiation complex that activates 5S RNA gene transcription (20, 21) . Since TFIIIA is expressed at very high levels in immature (fully grown prophase I-arrested) oocytes, slightly lower levels in mature (metaphase II-arrested) oocytes, and extremely low levels in somatic cells, Pfaff et al. (17) constructed the Xenopus laevis oocyte expression vector pOEV, which allows cloned DNA to be transcribed and translated directly in the immature oocyte. They demonstrated that vector transcription is driven by the TFIIIA gene promoter, which within 2 days can generate 1 -2 ng per oocyte of stable mRNA template for translation. We constructed the d2EGFP gene downstream of the TFIIIA promoter, and we also found that its expression in the oocyte was driven by this promoter (Fig. 3E) . Thus, in our PPRE regulatory system, human PPARγ was expressed because of the TFIIIA gene promoter (XOE) function. PPARγ is a ligand-activated transcription factor that binds a specific DNA responsive element (PPRE) in the promoter of its target gene (22) . PPARγ binds to the gene regulatory element, PPRE, in plasmid pLXRN-PPRE-d2EGFP, driving expression of the d2EGFP gene downstream of PPRE. PPARγ is activated by a range of compounds including hypolipidemic drugs, fatty acids, prostanoids, and TZDs (synthetic high affinity antidiabetic agents).
We chose a destabilized variant of the enhanced green fluorescent protein (d2EGFP) as the target for evaluating the efficiency of PPRE. Unlike the unmodified EGFP protein, which is extremely stable, d2EGFP has an in vivo half-life of approximately two hours (23) . Therefore, it provides a more accurate measurement of transient activation by PPRE than unmodified EGFP, and is ideal for kinetic studies of gene activation. Using prostanoids or TZDs as the control drugs, this system proved efficacious for rapid selection or evaluation of a drug that has potential for regulating LDL expression through an effect on the PPRE regulatory pathway. With this system, we quickly selected hawthorn flavonoids from other natural medicines.
Since Gurdon's experiment (14) , the Xenopus oocyte, particularly the fully-grown oocyte in stage V -VI, has become an attractive model for studies involving in vitro synthesis of exogenous proteins. In contrast to somatic cells in vitro, the medium for Xenpous oocyte culture is composed of inorganic compounds and antibiotics. The other great advantage is that the Xenopus oocyte has a large nucleus, which makes intranuclear microinjection possible.
As shown in Table 1 , hawthorn flavonoids and PE1 increased the expression of endogenous LPL in waterinjected oocytes, and this effect was markedly enhanced by injection of exogenous PPARγ. The results imply that there is an endogenous PPRE regulatory system in Xenopus oocytes, which could be responsive to exogenous PPARγ.
In vivo experiments (see Table 2 ) demonstrated that hawthorn flavonoids mediated LPL expression in mice. LPL plays an important role in lipoprotein metabolism and is expressed in various tissues, especially adipose and muscle tissue, where it plays different roles. Muscle contains at least half the total body LPL, and the free fatty acids generated by muscle LPL are catabolized for energy. Therefore, changes in muscle LPL could greatly affect the partitioning of circulating lipid between adipose tissue and muscle (24) . The adipose / muscle LPL ratio is important in the control of lipid partitioning. A higher ratio means that more free fatty acids flow to adipose tissue for storage or to muscle tissue for oxidation. By estimating the total LPL contents of muscle and adipose tissue, Bessesen et al. (25) demonstrated that muscle, not adipose tissue, was the primary site of chylomicron triglyceride fatty acid clearance.
The purity of the flavonoids we tested was 93.8%. The composition of the remaining 6.2%: water ≤2.0%, and the others were unknown, but according to the studies on the chemical constituents from the leaves of hawthorn, they might be ursolic acid, daucosterol, or nonacosanol, and so on. According to numerous in vivo animal experiments and clinic studies, it was believed that flavonoids were the compounds in hawthorn that had the function of heart protection and lipid mediation.
In conclusion, our results suggest that hawthorn flavonoids increase LPL expression through a PPARγ-dependent mechanism. Hawthorn flavonoids comprise an array of substances such as vitexin, vitexin-rhamnoside, vitexin-glucoside, rutin, hyperoside, pinnatifin, and quercetin, any of which may have direct or indirect effects on this mechanism. Further research might be directed towards identification of the component(s) that affect the PPARγ pathway as PPARγ-ligands. Our in vivo experiments showed that both hawthorn flavonoids and PE1 increased LPL significantly in muscle tissue and decreased it in adipose tissue. The decreased adipose / muscle LPL ratio indicates that hawthorn flavonoids may promote fat / carbohydrate oxidation and reduce lipid accumulation in adipose tissue by regulating LPL expression and controlling lipid partitioning in vivo, suggesting that they may have the function of promoting chylomicron triglyceride fatty acid clearance through their pleiotropic effects.
